Showing results (141-150 of 161) with videos related to

Sort By:
Pageof 17
Arthritis and Rheumatism|May 20, 1998
Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United StatesR C Lawrence, C G Helmick, F C Arnett, et al.
Clinical and Experimental Rheumatology|August 4, 2009
Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosisJ D Finkielman, P A Merkel, D Schroeder, et al.
Annals of the Rheumatic Diseases|May 9, 2007
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosisPhilip J Clements, Michael D Roth, Robert Elashoff, et al.
Annals of Internal Medicine|February 1, 1994
Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind studyF M Wigley, R A Wise, J R Seibold, et al.
Clinical and Experimental Immunology|January 12, 2017
Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitisJ M Clain, A M Hummel, J H Stone, et al.
The Journal of Rheumatology|October 21, 1999
A disease severity scale for systemic sclerosis: development and testingT A Medsger, A J Silman, V D Steen, et al.
Annals of the Rheumatic Diseases|April 17, 2008
EULAR recommendations for the management of primary small and medium vessel vasculitisC Mukhtyar, L Guillevin, M C Cid, et al.
Annals of the Rheumatic Diseases|April 17, 2008
EULAR recommendations for the management of large vessel vasculitisC Mukhtyar, L Guillevin, M C Cid, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 18, 2015
Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoidsE M Miloslavsky, U Specks, P A Merkel, et al.
Rheumatology (Oxford, England)|June 27, 2001
Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trialD E Furst, P J Clements, W K Wong, et al.
Pageof 17